Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409055 | 0.88 | TACR1 (0.43) | TACR1RAB9A | |
| SCHEMBL15292153 | 0.88 | MME (0.47) | — | |
| SCHEMBL27256763 | 0.88 | MME (0.47) | — | |
| SCHEMBL18812052 | 0.88 | MME (0.47) | — | |
| SCHEMBL20454197 | 0.88 | MME (0.47) | — | |
| SCHEMBL16197554 | 0.88 | MME (0.47) | — | |
| SCHEMBL16197553 | 0.88 | MME (0.47) | — | |
| SCHEMBL20346848 | 0.87 | ALDH1A1 (0.53) | — | |
| SCHEMBL20160081 | 0.87 | ALDH1A1 (0.53) | — | |
| SCHEMBL903575 | 0.87 | ALDH1A1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | SEATTLE GENETICS, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-8992932-B2 | Binder-drug conjugates (ADCs) and use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987209-B2 | N-carboxyalkyl-auristatin and the use thereof | SEATTLE GENETICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20130261064-A1 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | disclosed |
| WO-2013087716-A2 | NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | Bayer Pharma AG (DE) | 2013-04-18 | — | — | US | disclosed |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012143496-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143495-A2 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012041805-A1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122024-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | MDN1, EPCAM, VCAM1 | TACR1 495/4885RAB9A 3070/4885HPGD 2707/4885 |
| US-20130066055-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | TACR1 885/4885RAB9A 1941/4885HPGD 2858/4885 |
| US-20160193359-A1 | NEW BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | TACR1 885/4885RAB9A 1941/4885HPGD 2858/4885 |
| US-20130261064-A1 | N-CARBOXYALKYL-AURISTATIN AND THE USE THEREOF | HDGF, HGF, HGFAC | TACR1 2644/4885RAB9A 4450/4885HPGD 3078/4885 |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | HDGF, HGFAC, HGF | TACR1 2782/4885RAB9A 4409/4885HPGD 2837/4885 |
| US-20140127240-A1 | Novel Binder-Drug Conjugates (ADCs) and Use of Same | DDR1, IGFBP6, KDR | TACR1 979/4885RAB9A 2663/4885HPGD 2237/4885 |
| US-20150246136-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME | DDR1, IGFBP6, KDR | TACR1 979/4885RAB9A 2663/4885HPGD 2237/4885 |
| US-20130095123-A1 | New binder-drug conjugates (ADCs) and use thereof | CDK4, CDKL4, FLT4 | TACR1 885/4885RAB9A 1941/4885HPGD 2858/4885 |
| US-20150030618-A1 | NOVEL BINDER-DRUG CONJUGATES (ADCS) AND USE THEREOF | CDK4, CDKL4, FLT4 | TACR1 908/4885RAB9A 1848/4885HPGD 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.